Victoza side effects on TikTok: what's real vs. overhyped

What did @iamlmichelle actually say?

The creator shared three personal observations from taking Victoza (liraglutide): appetite dropped "immediately" on day one, she felt the injection "activating" in her body within a minute or two of the shot, and her blood sugar levels have been coming down. She also acknowledged needing better food choices, even with reduced appetite. These are honest, first-person observations, not medical advice, and that framing matters when evaluating them.

The video is personal testimony, not a clinical tutorial. Still, 86,000 views means a lot of people are treating it as a reference point for what to expect on liraglutide. Two of the three claims hold up reasonably well. One is worth digging into.

Does the science back this up?

Mostly, yes, with one notable exception. Liraglutide's appetite-suppressing effects are well-documented. It works by mimicking GLP-1, a hormone that signals satiety to the brain, slows gastric emptying, and reduces food intake. The blood sugar reduction claim is straightforward, supported by the drug's entire clinical foundation.

The "activating" sensation within minutes of injection is where things get scientifically murky. Liraglutide is a subcutaneous injection with a half-life of around 13 hours. It does not activate in the bloodstream within 60 to 120 seconds. Peak plasma concentration takes 8 to 12 hours after injection (Novo Nordisk prescribing information, 2017). What she likely felt was a localized injection-site sensation, a mild autonomic response, or the nocebo/placebo effect, not pharmacological activation. This is worth correcting because people new to injectables may misread normal or unrelated sensations as drug effects.

On appetite reduction: the LEAD-3 trial (Garber et al., 2009, The Lancet) confirmed significant appetite suppression with liraglutide 1.2 mg and 1.8 mg compared to glimepiride. Onset of GLP-1 receptor activity begins within hours of first dosing, which is consistent with some early appetite changes.

What did they get wrong (or right)?

Credit where it is due: the claim that liraglutide helps "decrease my blood sugar" is accurate and not oversold. She does not claim it cures diabetes or that she stopped other treatments. The appetite decrease observation is also well-supported, and she is honest that "it's still some work," which reflects reality. GLP-1 agonists are not magic switches.

What she got wrong is the "minute or two afterwards" activation claim. That is not how liraglutide pharmacokinetics work. The drug is absorbed slowly from subcutaneous tissue. There is no mechanism for a felt systemic effect within 120 seconds of injection. This is a common misattribution with injectables, people feel something physical during or after injection and connect it to the drug's action. It is understandable but inaccurate.

She also does not mention common side effects like nausea, vomiting, or injection site reactions, which affect a significant portion of users (Davies et al., 2015, Diabetes Care). That is not a criticism of her honesty, but viewers deserve to know the full picture.

What should you actually know?

If you are starting liraglutide or any GLP-1 receptor agonist, here is what the clinical record actually supports. Appetite suppression can begin early, sometimes within the first days, because GLP-1 receptors in the hypothalamus respond relatively quickly. Blood sugar improvement typically takes longer to show meaningfully on labs, though fasting glucose can start shifting in the first weeks.

The "feeling it activate" experience she describes is not pharmacologically supported for a subcutaneous injection. If you feel something odd right after an injection, it is more likely injection technique, a nerve near the site, or an anxiety response. That does not mean she did not feel something real. It means the cause is probably not the drug hitting your system in two minutes.

One thing she gets right without knowing the clinical language: liraglutide does not replace dietary quality. Reduced appetite does not equal improved nutrition. Research consistently shows that GLP-1 users who pair the medication with dietary changes get better metabolic outcomes (Pi-Sunyer et al., 2015, New England Journal of Medicine). Her instinct to eat better, not just less, is sound.

Bottom line

Two out of three observations are grounded in real pharmacology. The rapid "activation" sensation is not, and it is the kind of thing that spreads misinformation about how injectables work. The creator is transparent about her experience and does not overclaim, which is more than can be said for a lot of GLP-1 content on TikTok. But feelings are not mechanisms, and viewers should know the difference.